Loading…
Chinese biotech developing toripalimab, a PD-1 cancer immunotherapy antibody approved in China and the US (as Loqtorzi via partner Coherus).
Chinese biotech developing toripalimab, a PD-1 cancer immunotherapy antibody approved in China and the US (as Loqtorzi via partner Coherus).
Sells toripalimab to Chinese hospitals, where a place on the national reimbursement list opens volume at lower prices, and earns licence fees and milestone payments from partners abroad: Coherus holds the US and Canada rights under a 2021 deal. Heavy spending on trials and the antibody pipeline makes partner payments a second income stream.
In one line: A Chinese immuno-oncology biotech, akin to a smaller BeiGene.
Moat: narrow (IP / patents, regulatory licence). First Chinese-developed PD-1 antibody approved in the US, protected by patents and regulatory approvals.
Headquarters: Shanghai, China · Founded: 2012 · Employees: 2,903
Size Shanghai Junshi Biosciences (688180.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.06B, the 631st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥30.85 on 6 Nov 2026.
Performance Over six months the shares fell 23.6%, against +4.5% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 29.1% over the last twelve months (peer median +5.4%); the operating margin is -14.6% (peer median 15.7%).
Valuation It trades at 9.3× enterprise value to sales against a peer median of 3.0× (most expensive of 18).
Capital Return on invested capital runs 7.0 points below its cost of capital (5.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.21B | CN¥2.49B | CN¥1.94B | CN¥1.50B | CN¥1.45B |
| Revenue growth | — | +28% | +30% | +3% | — |
| Gross profit | CN¥2.75B | CN¥1.81B | CN¥1.31B | CN¥714M | CN¥718M |
| EBITDA | n/a | -CN¥615M | -CN¥1.01B | -CN¥2.18B | -CN¥2.45B |
| Net income | -CN¥429M | -CN¥875M | -CN¥1.28B | -CN¥2.28B | -CN¥2.39B |
| Free cash flow | -CN¥748M | -CN¥1.25B | -CN¥2.07B | -CN¥2.73B | -CN¥2.11B |
| Capital expenditure | CN¥787M | CN¥768M | CN¥691M | CN¥833M | CN¥394M |
| Total debt | CN¥6.82B | CN¥4.14B | CN¥2.93B | CN¥1.79B | CN¥1.32B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences 688180.SS | $4.06B | -24% | +29% | -15% | 9.3× | n/a |
| BeOne Medicines Ltd. Sponsored ADR ONC | $43.3B | +30% | +34% | 15% | 6.5× | 16.4% |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 7.4× | 11.7% |
| Merck & MRK | $362B | +33% | +5% | 18% | 5.4× | 4.1% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 8.8× | 14.9% |
| Akeso 9926.HK | $10.2B | -38% | +42% | -25% | 19.5× | n/a |
| Shanghai Henlius Biotech 2696.HK | $3.41B | -37% | +33% | 12% | 3.7× | 15.2% |
| CStone Pharmaceuticals 2616.HK | $1.07B | -38% | +117% | -89% | 14.8× | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688180.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.7% | +6.9% | 5th lowest of 21 |
| 6-month return | -23.6% | +4.5% | 2nd lowest of 21 |
| Distance from 52-week high | -33.7% | -21.0% | 4th lowest of 21 |
| Revenue growth (TTM) | +29.1% | +5.4% | 4th highest of 20 |
| Operating margin | -14.6% | 15.7% | lowest of 18 |
| EV / Sales | 9.3× | 3.0× | most expensive of 18 |
| ROIC minus cost of capital | -7.0 pp | +7.8 pp | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences 688180.SS | China | $4.06B | -24% | +29% | -15% | 9.3× | n/a | n/a |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 2.8× | -11.5% | +0.3% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 2.4× | 20.2% | +6.2% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 5.6× | 17.8% | -5.8% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 3.0× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 8.6× | 0.7% | +192.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 4.5× | 1.5% | +12.1% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 3.4× | 7.3% | +5.9% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 1.9× | -5.2% | +3.2% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 3.5× | 5.0% | +7.5% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 6.6× | 23.8% | +13.8% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 0.6× | -5.3% | +7.8% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 2.8× | 6.3% | +4.5% |
| Livzon Pharmaceutical 000513.SZ | China | $3.71B | -4% | -14% | 19% | 2.2× | -9.8% | +2.7% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 6.5× | 3.3% | +45.1% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 4.3× | 14.9% | +12.7% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 2.4× | 16.7% | +19.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 1.8× | -4.5% | -1.0% |